Thus, decreased Drp1 GTPase activity has demonstrated neuroprotective outcomes in experimental models of AD, suggesting that targeting Drp1 may offer a promising route to alleviate AD-related neurodegeneration [65]. Here, DNM1L is linked to Alzheimer disease.